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TAp63a, a homolog of the p53 tumor suppressor, is
a quality control factor in the female germline.
Remarkably, already undamaged oocytes express
high levels of the protein, suggesting that TAp63a’s
activity is under tight control of an inhibitory mecha-
nism. Biochemical studies have proposed that
inhibition requires the C-terminal transactivation
inhibitory domain. However, the structural mecha-
nism of TAp63a inhibition remains unknown. Here,
we show that TAp63a is kept in an inactive dimeric
state. We reveal that relief of inhibition leads to
tetramer formation with20-fold higher DNA affinity.
In vivo, phosphorylation-triggered tetramerization of
TAp63a is not reversible by dephosphorylation.
Furthermore, we show that a helix in the oligomeriza-
tion domain of p63 is crucial for tetramer stabilization
and competes with the transactivation domain for
the same binding site. Our results demonstrate how
TAp63a is inhibited by complex domain-domain
interactions that provide the basis for regulating
quality control in oocytes.
INTRODUCTION
In mammals, the family of the p53 tumor suppressor contains
two additional members, p73 and p63 (Kaghad et al., 1997;566 Cell 144, 566–576, February 18, 2011 ª2011 Elsevier Inc.Schmale and Bamberger, 1997; Senoo et al., 1998; Trink et al.,
1998; Yang et al., 1998). Originally, their discovery had sparked
the speculation that tumor suppression might be achieved by an
entire network of p53-like factors. However, detailed studies
have revealed that both p53 homologs serve important develop-
mental functions (Mills et al., 1999; Yang et al., 1999, 2000). p73
knockout mice suffer from hippocampal dysgenesis, chronic
infections and inflammation, as well as abnormalities in phero-
mone sensory pathways. Loss of p63 results in evenmore severe
defects, including limb truncations, lack of a multilayered skin,
and other epithelial structures. These phenotypes led to the
identification of six p63-related syndromes in humans that are
characterized by deformation of the limbs and/or skin abnormal-
ities (Celli et al., 1999; McGrath et al., 2001). In contrast to these
clear developmental functions the question if both proteins also
act as tumor suppressors is still debated.
The investigation of the physiological role of both proteins is
further complicated by the existence of many different isoforms
of p63 and p73 and potentially by the formation of mixed oligo-
mers between both proteins (Coutandin et al., 2009; Joerger
et al., 2009) (Figure 1A). Isoforms are created by combining
several different C-terminal splice variants (De Laurenzi et al.,
1999; Kaghad et al., 1997; Yang et al., 1998) with two different
promoters that produce isoforms either with (TA isoforms) or
without (DN isoforms) the N-terminal transactivation domain
(Yang et al., 1998).
In the case of p63, detailed analysis has started to reveal the
physiological functions of some isoforms. DNp63a, the isoform
produced by combination of the second promoter with the
longest C-terminal splice variant, plays an important role in the
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Figure 1. TAp63a Is Kept in an Inactive Dimeric State
(A) Comparison of the domain structure of p53, TAp63a, TAp63g, and DNp63a
showing the transactivation (TA) domain, DNA binding domain (DBD), oligo-
merization domain (OD), sterile a-motive (SAM) domain, and transactivation
inhibitory (TI) domain.
(B) SEC chromatogram of TAp63a (green), MBP-TAp63a (black), MBP-
TAp63aFTL (red), and MBP-TAp63g (blue) purified from E. coli. Apparent
molecular weights are indicated. Void volume and elution volumes of globular
standard proteins with corresponding molecular weights are shown on the
x axis.
(C) Bar diagram showing relative accessibilities of cysteines in MBP-TAp63a
(black) and MBP-TAp63aFTL (red) as monitored by binding of a maleimide-
biotin conjugate. The value of MBP-TAp63a is set to 100%. Error bars show
standard deviation.
(D–G) Change of differential refractive index (dRI, solid line) and of the
molecular weight of the protein peak (MW, dotted line) in SEC-MALS analysis of
MBP-TAp63a (D), TAp63a (E), MBP-TAp63aFTL, (F) and MBP-TAp63g (G).
Calculated molecular weights are displayed.
See also Figure S1 and Table S1.development of stratified epithelial tissues including skin by
maintaining a stem cell population in the basal layer (Senoo
et al., 2007). Inactivation of this isoform seems to be responsiblefor the severe developmental defects seen in the knockout mice
as well as in human patients with p63 mutations. In contrast,
TAp63a, the isoform containing the long a C terminus and the
full N-terminal transactivation domain, serves a quite different
function. It is found in oocytes where it acts as a quality control
factor that monitors the genetic stability of these cells (Suh
et al., 2006). TAp63a expression in murine oocytes can be
detected from day E18.5 on and at day P5, whenmurine oocytes
are arrested in prophase of meiosis I, all oocytes show strong
nuclear expression. After oocytes are recruited for ovulation,
TAp63a expression is lost. Previous experiments have shown
that g-irradiation results in phosphorylation of TAp63a followed
by the elimination of all premature oocytes while mature ones
that do not express p63 are not affected (Suh et al., 2006).
Due to its ability to induce cell death the activity of TAp63a
must be regulated very tightly. In contrast to p53 that is kept at
very low concentrations in nonstressed cells and only increases
when triggered by oncogenic signals (Brooks and Gu, 2006;
Wade et al., 2010), TAp63a reaches high expression levels
already in nonstressed oocytes (Suh et al., 2006). This observa-
tion has suggested that the activity of TAp63amust be regulated
by keeping it in an inactive state. In cell culture-based transacti-
vation experiments TAp63a indeed showed only a very low tran-
scriptional activity. By deletion mutagenesis we have revealed
in previous experiments that the last 70 amino acids of TAp63a
act as a transactivation inhibitory domain (TID). Deletion ormuta-
tion of this TI domain increases TAp63a’s low transcriptional
activity severalfold (Serber et al., 2002; Straub et al., 2010;
Yang et al., 1998). The exact mechanism of how the TID inhibits
the activity of TAp63a, however, remained unknown.
Here, we show both in vitro and in vivo that TAp63a is kept in
a closed dimeric conformation in nonstressed oocytes while
g-irradiation-triggered phosphorylation promotes the formation
of active tetramers. The active state of TAp63a is stabilized by
a special structure of its tetramerization domain, making the
activation process essentially irreversible.
RESULTS
TAp63a Forms a Closed Dimeric Conformation
To characterize the inhibitory mechanism of the TID we ex-
pressed murine TAp63a in Escherichia coli. Surprisingly, size
exclusion chromatography (SEC) analysis of purified TAp63a
suggested that it forms dimers instead of the expected tetramers
(Figure 1B). All mammalian members of the p53 protein family
use a highly conserved oligomerization domain (OD) to form
tetramers that were shown to be the active state (Chan et al.,
2004; Chene, 2001; Jeffrey et al., 1995; Lee et al., 1994). The
concentration of TAp63a used in the SEC experiment was orders
of magnitude higher (3–15 mM) than the KD for tetramerization of
p63 (12 nM) (Brandt et al., 2009), excluding the possibility that
simple dilution can explain the absence of tetramers. This result
implies that TAp63a adopts a dimeric, inactive conformation and
further suggests that activation of p63 may be linked to the
formation of tetramers. To address this question, we performed
SEC analysis with the transcriptionally active TAp63g isoform
that lacks the TID. Obtaining soluble TAp63g required its expres-
sion as an N-terminal maltose-binding-protein (MBP) fusion. ForCell 144, 566–576, February 18, 2011 ª2011 Elsevier Inc. 567
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Figure 2. Activation of TAp63a by Phosphorylation in Oocytes Leads
to Tetramerization
(A) Western blot of murine oocyte samples. p63 signals in the lysate of murine
oocytes, SEC elution fractions at 1.3 ml (tetrameric protein) and 1.55 ml
(dimeric protein) for both nonirradiated (NIRR) and g-irradiated (IRR) oocytes
are displayed.
(B) Western blot of SEC elution fractions from 1.2 to 1.65 ml of NIRR ovary
lysate.
(C) Bar diagram showing relative p63 signal intensities of the western blot
shown in (B). The sum of the intensities of all fractions was set to 100%.
(D and E) Corresponding data and analysis for IRR ovary lysate.
See also Figure S2.comparability we also expressed TAp63a fused to MBP. SEC
analysis of MBP-TAp63g showed that it behaves as a signifi-
cantly larger protein than MBP-TAp63a despite the fact that it
contains 193 amino acids less per monomer (Figure 1B).
In a previous alanine scanning experiment of the TID, we have
found that the triple mutant F605A T606A L607A (TAp63aFTL)
shows high transcriptional activity suggesting that this mutation
destroys the inhibitory function of the TID (Straub et al., 2010).
SEC analysis showed that MBP-TAp63aFTL also behaves as
a much larger protein than MBP-TAp63awith a retention volume
similar to MBP-TAp63g (Figure 1B).
The classification of TAp63a as a dimer was based on a
calibration of the SEC column with compact globular proteins.
The predicted molecular weights of 160 kDa for TAp63a and
266 kDa for MBP-TAp63a closely resemble the theoretical
values for the dimers of 150 and 232 kDa, respectively. Estima-
tion of the molecular weights of MBP-TAp63aFTL and MBP-
TAp63g, however, resulted in values exceeding the theoretical
ones for the assumed tetramers by far. These findings could
be explained either if the active forms adopt an oligomeric state
higher than tetrameric, if the protein aggregates or if the confor-
mation of the tetramers deviates from a globular fold. To investi-
gate the oligomeric state of all proteins by determining their
mass independently of their shape, we used multiangle light
scattering (MALS) analysis. The results shown in Figures 1D–
1G confirm that TAp63a and MBP-TAp63a form dimers, while
MBP-TAp63aFTL and MBP-TAp63g exist as tetramers. The
homogeneity of the SEC peaks demonstrated by MALS analysis
further excludes the possibility that the proteins aggregate.
The absence of aggregation and the formation of specific oligo-
meric states are further supported by crosslinking experiments
(see Figures S1A–S1D available online), by mass spectrometry
(LILBID) analysis (Figure S1E) and sedimentation equilibrium
analytical ultracentrifugation (Figure S1F and Table S1). The
combination of all these data suggests that the deviation of the
apparent molecular weight from the calculated one originates
from the formation of an open, nonglobular conformation. To
further investigate this hypothesis we performed a cysteine
accessibility assay that demonstrated that cysteines can be
more easily chemically modified in the MBP-TAp63aFTL mutant
than in the nonmutated form (Figure 1C; Figure S1I). In addition,
the formation of an open conformation was supported by the
analysis of sedimentation velocity ultracentrifugation experi-
ments (Figures S1G and S1H).
Phosphorylation Triggers the Formation of Active
TAp63a Tetramers In Vivo
In mice, expression of TAp63a can be detected from embryonic
day 18.5 onwith all oocytes showing strong expression at day P5
when murine oocytes are arrested in prophase of meiosis I
(dictyate arrest) (Suh et al., 2006). p63 expression is maintained
at a high level until oocytes are recruited for ovulation. DNA
damage during this time triggers activation of p63 and
destruction of the oocytes. To investigate if our results obtained
in vitro can explain the behavior of TAp63a in oocytes, we
analyzed the oligomeric state of TAp63a in 5-day-old mice by
SEC. Figure 2A shows that g-irradiation of micewith 0.52 Gy trig-
gers phosphorylation of TAp63a and leads to a reduction of its568 Cell 144, 566–576, February 18, 2011 ª2011 Elsevier Inc.concentration relative to nonirradiated oocytes. Analysis of the
SEC fractions of samples obtained from nonirradiated mice
revealed a strong signal in the dimer fraction (1.55 ml) and no
detectable signal in the tetramer fraction (1.3 ml, calibrated
with bacterially expressed p63 isoforms; Figures S2A–S2C and
Figures 2A–2C). In contrast, samples obtained from irradiated
mice showed a significant signal in the tetramer fraction (Figures
2A, 2D, and 2E). The in vivo concentration of tetrameric TAp63a
in irradiated oocytes is expected to be significantly higher than
seen in the SEC experiments since oocyte lysis and SEC analysis
lead to a minimum 10-fold dilution of the sample. We confirmed
that dilution shifts the equilibrium toward dimers by reducing the
concentration of bacterially expressed MBP-TAp63g in SEC
experiments (Figures S2C–S2G).While virtually exclusively tetra-
meric at a concentration of 3–15 mM, MBP-TAp63g displays an
almost equal distribution between dimers and tetramers at
30 nM (Figure S2). These results indicate that TAp63a in non-
stressed oocytes is kept in a dimeric and closed conformation
and that DNA damage triggers the formation of tetramers
in vivo. The significantly higher concentration of TAp63a in
nonirradiated versus irradiated cells further suggests that the
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Figure 3. Functional Consequences of Tetramer Formation
(A–C) DNA-binding of MBP-TAp63a (A), MBP-TAp63aFTL (B), and MBP-
TAp63g (C) from E. coli to the p21 response element measured by fluores-
cence anisotropy. Solid lines show the fit to a two-binding-site model (see
Supplemental Information). Error bars show standard deviation.
(D) Western blot of SEC elution fractions between 1.1 and 1.7 ml of IRR ovary
lysate without l-phosphatase treatment.
(E) Bar diagram representing the relative p63 intensities of the western blot
shown in (D).
(F and G) Corresponding western blot and bar diagram for IRR lysate with
l-phosphatase treatment are shown in (F) and (G), respectively.
(H) Bar diagram showing ratios between the sum of the signal intensities of
tetramer (1.10–1.40 ml) and dimer (1.45–1.70 ml) fractions of SEC elution
fractions of ovary lysate without (IRR – lPP) and with (IRR + lPP) l-phos-
phatase treatment.
See also Figure S3.formation of tetramers is not suppressed by keeping the intracel-
lular concentration low (as it is discussed for p53) but actively by
domain-domain interactions involving the TID.
Tetramerization Increases the DNA Binding Affinity
We next investigated the functional consequences of tetramer
formation. Previous experiments in oocytes have demonstrated
that phosphorylation increases TAp63a’s DNA binding affinity
20-fold (Suh et al., 2006). To investigate if this increase in DNA
affinity can be explained by the formation of tetramers, we
measured KD values for the binding of MBP-TAp63a, MBP-
TAp63aFTL, and MBP-TAp63g to the p21 promoter response
element using fluorescence anisotropy. Figures 3A–3C (and
Figures S3A and S3B) reveal that dimeric MBP-TAp63a binds
the p21 promoter response element with a KD of 7.51 ± 1.32 mM.
For tetrameric MBP-TAp63aFTL and MBP-TAp63g, KD values of
0.38 ± 0.04 mM and 0.34 ± 0.08 mMwere measured, respectively.
Thesemeasurements demonstrate that the change from a closed
dimeric to an open tetrameric state increases the DNA binding
affinity by 20-fold, similar to the studies carried out in oocytes.
Phosphorylation Is Not Required for Maintaining
the Tetrameric State
Previous investigations have revealed that treatment of phos-
phorylated TAp63a with l-phosphatase does not decrease the
DNA binding affinity to its original value (Suh et al., 2006). This
result suggests that phosphorylation serves as a trigger for the
activationprocessbut is not essential tomaintain theactive state.
Since the active state is the tetramer, dephosphorylation should
not affect the oligomerization equilibrium. To investigate the influ-
ence of the phosphorylation status on the oligomeric state, we
performed SEC analysis of l-phosphatase-treated TAp63a
obtained from irradiated oocytes. The dephosphorylated sample
indeed showed a high percentage of tetramers and only
a relatively small increase in the dimer concentration compared
with phosphorylated TAp63a (Figures 3D–3H). In vitro control
experiments showed that l-phosphatase treatment leads to
complete dephosphorylation (Figures S3C and S3D). This result
suggests that tetramer formation constitutes an almost irrevers-
ible activation switch triggered by phosphorylation. Recently, we
and others have discovered that p63 contains an additional helix
within its oligomerization domain (OD) that is not present in the
p53OD (Coutandin et al., 2009; Joerger et al., 2009). This second
helix stabilizes the tetramer by reaching across the tetrameric
interface. Since this helix must adopt a different conformation
or orientation within the closed dimeric state, it might be the
element that locks TAp63a in its tetrameric form after phosphor-
ylation induced activation. This model is supported by the
observation that deletion of this helix renders the active-state
mimetic mutant TAp63aFTL dimeric while deletion had no effect
on TAp63a (Figure 4). Furthermore, transactivation assays
revealed that deletion of the second helix significantly reduced
the transcriptional activity (Figure S4).
The Tetramerization Domain Is Essential for Forming
the Closed Conformation
Thismodel of regulating the activity of p63 by controlling the olig-
omerization state assigns a pivotal role to the tetramerizationdomain (as TD we define the OD with the second helix). The
structure of the TD is a dimer of dimers (Jeffrey et al., 1995;
Lee et al., 1994). The most obvious model would explain theCell 144, 566–576, February 18, 2011 ª2011 Elsevier Inc. 569
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Figure 4. The Second Helix of the TD Is Essential for Tetramer Formation
(A) Western blot of SEC elution fractions between 1.05 and 1.70 ml of TAp63a expressed in rabbit reticulocyte lysate (RRL) using an anti-myc antibody.
(B) Bar diagram showing the relative p63 intensities of the western blot shown in (A). Corresponding data and analysis of TAp63aFTL, TAp63aDHelix, and
TAp63aFTLDHelix are shown in (C and D), (E and F), and (G and H), respectively.
See also Figure S4.inhibition of TAp63a by selective blocking of the tetramerization
interface without affecting the dimerization interface. To probe
the importance of the tetramerization interface we mutated
Met374 to Gln and Ile378 to Arg (TAp63aMI). Mutations of
analogs’ position in p53 have been reported to trigger dimeriza-
tion (Davison et al., 2001) (Figures 5A and 5B). These mutations
increased the transcriptional activity significantly, reaching 55%
activity of wild-type TAp63g (Figure 5E), similar to the activity of
dimeric p53 and TAp63g mutants (Davison et al., 2001; Straub
et al., 2010). Previous GST pull-down assays had shown that
the TID and the TA domain interact with each other (Serber
et al., 2002; Straub et al., 2010). In pull-down assays with an
external TI domain the TAp63aMI mutant was effectively pulled
down, in contrast to wild-type TAp63a (Figures 5F and 5G), sug-
gesting that TAp63aMI forms an open conformation in which the
TA is accessible for interaction. Consequently, this result
predicts that the TID in TAp63aMI should also be accessible
for interaction with an external TA domain. Indeed, this assump-
tion was confirmed in pull-down experiments (Figures 5H and 5I).
Taken together, these results demonstrate that this double
mutation induces an open conformation by disrupting the inhib-
itory mechanism mediated by the TID.
Met374 and Ile378 are located in the center of the tetrameriza-
tion interface. We also mutated Leu384 and Met385, located at
its edge, to Ala (Figures 5A, 5C, and 5D). The L384A and
L384A/M385A mutants (TAp63aL and TAp63aLM) showed
very low activity in transactivation assays and no interaction in
pull-down experiments with an external TID or TA domain
(Figures 5E–5I), demonstrating that only mutations in the central
region of the tetramerization domain disrupt the inhibitory mech-
anism by creating an open dimeric form (Figure S5).
An attractive model of the inhibitory mechanism would explain
the formation of dimeric TAp63a by direct interaction of the TID
with the tetramerization interface. In principle, NMR titration
experiments would allow a direct mapping of the binding site.
However, the p63 OD is tetrameric at concentrations typically
used for NMR (even without the second helix) rendering the
tetramerization interface inaccessible for a potential interaction570 Cell 144, 566–576, February 18, 2011 ª2011 Elsevier Inc.with the TID. Consequently, NMR titrations of the p63 OD with
a peptide derived from the TID (601–616) containing the FTL
motif did not show any interaction. Interestingly, titration exper-
iments of the p73 OD known to exist as a mixture of dimers and
tetramers (Coutandin et al., 2009) with the p63 TID peptide
resulted in the disappearance of all peaks by the formation
of soluble aggregates. Repeating this titration with the p73
TD that forms stable tetramers did not show any interaction
(data not shown). Although these experiments are quite indirect
and involve mixing of p63 and p73 domains, they suggest
that the p63 TID can interact with the p73 OD, but not with the
p73 TD, the difference being that the p73 OD exists in an equilib-
rium with dimeric forms with an accessible tetramerization
interface.
The N-Terminal Transactivation Domain Binds
to the OD of p63
Based on previous pull-down experiments, we had suggested
that formation of the closed state of TAp63a involves both the
N-terminal transactivation domain (TA) and the C-terminal TID
(Serber et al., 2002). To further investigate the importance of
the TA domain for the formation of the closed conformation,
we performed SEC analysis of DNp63a, a natural occurring
isoform lacking the first 45 amino acids (Yang et al., 1998).
As shown in Figure 6A, DNp63a is tetrameric demonstrating
that the simultaneous presence of both the TA and the TI
domains is necessary for the formation of a closed, dimeric
conformation.
To test whether the OD can interact with the TA domain we
titrated the p63 OD with peptides derived from the TA1 (9–32)
and TA2 (49–78) regions of the transactivation domain (Burge
et al., 2009). While the TA2 peptide did not interact, titrations
with the TA1 peptide showed strong chemical shift perturbations
(CSP) in the fast exchange regime (Figures 6B, 6C, and 6F).
Mapping these CSPs onto the OD structure revealed that the
binding site for this peptide overlaps with the location of the
second helix within the TD (Figure 6E). This result predicts that
the TA1 peptide should not interact with the TD of p63 which
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Figure 5. The TD of TAp63a Plays an Essential Role in Maintaining the Inhibited Dimeric State
(A) Sequence alignment of the TDs of human p73 and murine p63. Based on the structure of human p73 the structure of murine p63 was modeled. Conserved
regions are indicated by gray boxes. Amino acids that were mutated in p63 are shown in red, cyan, and orange.
(B–D) Structure of the human p73 TD (PDB accession code: 2KBY). Side chains of residues that are homologous to the amino acids mutated in p63 are shown
in the same colors as in (A). (B) shows mutations in TAp63aMI, (C) shows mutations in TAp63aL, and (D) shows mutations in TAp63aLM.
(E) Transcriptional activities on the p21 promoter in SAOS2 cells normalized to the protein concentration of TAp63aLM, TAp63aL, TAp63aMI, TAp63a, and
TAp63g. Error bars show standard deviation.
(F) Western blot of pull-down experiments with TAp63aLM, TAp63aL, TAp63aMI, TAp63a, and TAp63g from RRL using immobilized TID. Input (IP) and pull-down
(PD) are shown for each protein.
(G) Bar diagram showing the quantitative analysis of the pull-down experiments in (F). Error bars show standard deviation.
(H and I) Western blot (H) and corresponding bar diagram (I) showing the quantitative analysis of pull-down experiments with TAp63a, TAp63g, TAp63aFTL,
TAp63aMI, and TAp63aLM from RRL using immobilized TA domain. Error bars show standard deviation.
See also Figure S5.contains the second helix. Repeating the titration experiments
with the p63 TD indeed showed only very small chemical shift
changes (Figure 6B), suggesting that both the second helix of
the TD and the TA1 peptide compete for the same binding site.
The N-terminal transactivation domain of p53 contains three
important residues, Phe19, Trp23, and Leu26, that are known
to be involved in binding transcriptional coactivators andMdm2 (Horikoshi et al., 1995; Kussie et al., 1996; Lu and Levine,
1995; Thut et al., 1995). The crystal structure of a peptide derived
from the p53 transactivation domain in complex with Mdm2
showed that these three amino acids form one face of a helix
that is deeply buried in a hydrophobic pocket of Mdm2. All three
amino acids are conserved in p63. We hypothesized that
if binding of the N-terminal transactivation domain to the ODCell 144, 566–576, February 18, 2011 ª2011 Elsevier Inc. 571
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Figure 6. p63 TA1 Binds to the Oligomerization Domain of p63
(A) SEC chromatogram of His-MBP-DNp63aPPR purified from E. coli lacking the last 25 unstructured residues. The apparent molecular weight is indicated. Void
volume and elution volumes of globular standard proteins with corresponding molecular weights are shown on the x axis.
(B) Chemical shift perturbations (CSPs) on p63 OD (color coded) and p63 TD (gray) after addition of p63 TA1. OD residues are colored in blue, those with
CSP >0.1 ppm are shown in red and those with CSPs >0.05 ppm are shown in orange.
(C and D) [15N,1H]-TROSY spectra of 15N-labeled p63 OD in presence (red) and absence (blue) of p63 TA1 (C) and of p63 TA1FWL (D).
(E) Model of p63 TD based on the structure of human p73 TD. Residues are colored according to the code in (B). Helix H2 of the TD (white) lies on top of the TA1-
OD interaction interface. H2 is either shown as a ribbon or as a space-filling model.
(F) Sequences of p63 TA1 and p63 TA1FWL with the additional F10W mutation for UV280nm-based quantification.
(G and H) Western blot (G) and corresponding bar diagram (H) of SEC elution fractions between 1.05 and 1.70 ml of TAp63aFWL expressed in RRL using an anti-
myc antibody.
(I and J) Western blot (I) and corresponding bar diagram (J) of pull-down experiments with TAp63aFWL and DNp63a from RRL using immobilized TA domain.
Input (IP) and pull-down (PD) for each protein are shown in (I). For comparison, pull-down results for TAp63a and TAp63g from Figure 5H are shown. Error bars
show standard deviation.contributes to inhibition the most likely mechanism would
involve burying these three amino acids to prevent them from
interacting with the transcriptional machinery. Mutating these572 Cell 144, 566–576, February 18, 2011 ª2011 Elsevier Inc.residues to alanine resulted in a complete loss of interaction
with the OD, suggesting that they are indeed important for bind-
ing, probably by forming one face of a helix (Figures 6D and 6F).
ATA TD TI
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Figure 7. Model of the Inhibition of TAp63a
(A) Schematic representation of TAp63a showing the transactivation domain (TA), tetramerization domain (TD) and transactivation inhibitory domain (TI).
(B) Activation of TAp63a requires disruption of the TA-TID-TD interaction network resulting in an open conformation that enables tetramerization. Tetramers are
then stabilized by helix H2 in the TD that reaches across the tetramerization interface.Disrupting the interaction between the TA domain and the OD
by mutating these three important residues would expose the
binding site for the second helix, potentially leading to the forma-
tion of a tetrameric state. Indeed, mutating F16, W20, and L23 in
TAp63a to alanine (TAp63aFWL) results in the formation of tetra-
mers (Figures 6G and 6H). Furthermore, pull-down experiments
with an external TA domain revealed that the TID is accessible for
interaction as expected for an open and tetrameric state (Figures
6I and 6J). These data show that TAp63aFWL behaves similar to
DNp63a, which lacks the N-terminal part of the TA domain.
Model of the Structural Regulation of p63’s Activity
The data reported here suggest the following model for the regu-
lation of the activity of TAp63a in oocytes. In nonstressed
oocytes that are not recruited for ovulation yet, the protein is
kept in a dimeric, closed, and inactive conformation (Figure 7).
Both the N-terminal transactivation domain and the C-terminal
TID are required to form this closed state. The TD plays an essen-
tial role as a structural integration domain that interacts with the
TA on one side and potentially with the TID on the tetramerization
interface. Additional direct contacts between the TA and TI
domains have been shown by pull-down experiments (Serber
et al., 2002; Straub et al., 2010). The activity of this compact
dimeric form is reduced by decreasing its DNA-binding affinity
and probably further by burying important amino acids of the
TA. Activation requires phosphorylation which triggers a confor-
mational switch that releases the inhibitory interactions, allowing
TAp63a to tetramerize and to interact with the transcriptional
machinery through its TA. The active tetrameric state is stabi-
lized by the second helix of the TD that reaches across the inter-
face and occupies the binding site of the TA. This model explains
how TAp63a can reach high expression levels in oocytes without
inducing cell death. Activation of TAp63a, however, is an ‘‘irre-
versible’’ process that once started leads to the destruction of
the oocytes.
DISCUSSION
The model presented for the regulation of TAp63a’s transcrip-
tional activity differs significantly from the model proposed forp53, the most famous member of this protein family. The main
regulatory mechanism that determines the activity of p53 seems
to be its stability. In nonstressed cells p53 is kept at low concen-
trations through fast degradation by the E3 ubiquitin ligases
Mdm2 and Mdmx (Wade et al., 2010). Oncogenic signals result
in a stabilization of p53 leading to an increased cellular concen-
tration. TAp63a on the other hand, is already highly expressed in
nonstressed oocytes. DNA damage triggers a conformational
change that activates the protein. In contrast to p53, this active
form seems to bemore susceptible to degradation than the inac-
tive one (Figure 2A). This interpretation is supported by cell
culture experiments showing that transcriptionally inactive p63
forms accumulate to much higher concentrations than active
ones (Straub et al., 2010). Furthermore, it has been demon-
strated that efficient degradation requires an accessible TA
domain (Ying et al., 2005). Our NMR data indicate that the three
amino acids that are important for binding of p53 to Mdm2 and
that are conserved in p63 are most likely not accessible in the
inhibited dimeric conformation. While the interaction of p63
with Mdm2 is still discussed controversially, it is obvious that
interaction and possible degradation could only occur after acti-
vation and the formation of an open state of TAp63a. Regulating
the intracellular concentration of TAp63a most likely involves
other mechanisms, for example, other E3 ligases. To this end,
the Hect-domain E3 ligase ITCH has been shown to ubiquitinate
and promote the degradation of p63 (Rossi et al., 2006). Another
mechanism that might be specific for the closed dimeric confor-
mation is sumoylation that occurs at the very end of the C
terminus of TAp63a where a classical sumoylation site exists.
In cell culture experiments mutation of the sumoylation site
increased TAp63a’s intracellular concentration (Straub et al.,
2010). It might therefore be possible that the inhibited dimeric
form gets slowly degraded through sumoylation while the active
form becomes ubiquitinated by E3 ligases such as ITCH or
Mdm2. Degradation of activated TAp63amight occur in oocytes
that show a sublethal amount of DNA damage. Measurements of
dose-response curves have shown that g-irradiation with 0.1 Gy
results on average in one double-strand break per cell. Most of
the oocytes survive this condition with only a small fraction of
TAp63a becoming phosphorylated. Irradiation with 0.45 Gy,Cell 144, 566–576, February 18, 2011 ª2011 Elsevier Inc. 573
however, produces on average ten double-strand breaks per cell
and leads to the elimination of virtually all premature oocytes
(Suh et al., 2006). Degradation of activated TAp63amight there-
fore help to establish a certain threshold for the induction of
cellular death in oocytes.
A further difference between TAp63a and p53 is that TAp63a is
expressed in cells arrested in prophase of meiosis I, therefore
presumably inducing only cellular death and not cell cycle arrest
(although p63 can in principle induce cell cycle arrest; Guo et al.,
2009). From an evolutionary standpoint, quality control of the
genetic integrity of oocytes seems to be the original function of
the p53 family and cell cycle arrest and tumor suppression evolu-
tionary later developed abilities (Coutandin et al., 2010). This
hypothesis is based on the identification of p53-like genes in
invertebrate species, for example,Caenorhabditis elegans (Pear-
son and Sanchez Alvarado, 2010). Without renewable tissue and
with a relatively short life span, this worm does not require tumor
suppression mechanisms. However, its germ cells express
a p53-like protein, Cep-1. Both structurally and functionally
Cep-1 resembles more closely p63 (Derry et al., 2001; Ou et al.,
2007), suggesting that p63 and quality control in germ cells are
the ancestral member and function of this protein family.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification in E. coli
Genes for murine TAp63a, TAp63g, TAp63aFTL, and TAp63aR (TAp63a
carrying the mutation R279H in the DBD; Celli et al., 1999) were cloned into
pMAL-c4X vector (New England Biolabs, NEB). All proteins had an additional
C-terminal His6-tag. The gene for TAp63a was cloned in the pBH4 vector as
well (gift fromWendell Lim laboratory, UCSF) for expression with an N-terminal
His6-tag. The gene for murine DNp63a lacking the last 25 amino acids
(DNp63aPPR) was cloned into a modified pMAL vector leading to a fusion
protein having anN-terminal His6-tag followedbyMBP (His-MBP-DNp63a
PPR).
Proteins were expressed in T7 express competent E. coli cells (NEB) and puri-
fied using Ni-Sepharose Fast Flow (GE Healthcare) and Amylose resin (NEB)
according to standard protocols. Proteins were further purified by size exclu-
sion chromatography (SEC) using a preparative Superose 6 column (GE
Healthcare) in 10 mM potassium phosphate buffer (pH 7.6) with 200 mM
NaCl. All following experiments were performed in this storage buffer if not
denoted differently.
Protein Expression in Rabbit Reticulocyte Lysate (RRL)
N-terminally myc-tagged murine TAp63a, TAp63aFTL, as well as TAp63a and
TAp63aFTL lacking helix H2 in the TD (TAp63aDHelix, TAp63aFTLDHelix),
TAp63a triplemutantF16A,W20A,L23A (TAp63aFWL), TAp63adoublemutants
L384A/M385A (TAp63aLM)andM374Q/I378R (TAp63aMI), andTAp63amutant
L384A (TAp63aL), TAp63g, and DNp63a were expressed from pcDNA3.1
vector in RRL as described (Straub et al., 2010). Proteins were used for SEC
analysis with a Superose 6 PC 3.2/30 column (GE Healthcare).
Size Exclusion Chromatography
SEC of recombinant proteins expressed in E. coliwas performed at 16C using
aSuperose 610/300GLcolumn (GEHealthcare), calibrated usingBlueDextran
2000, Thyroglobulin (669 kDa), Ferritin (440 kDa), Aldolase (158 kDa), and
Ovalbumin (43 kDa) (GE Healthcare) (Figures 1A and 5A; Figure S2A). All other
SEC experimentswere performed at 4Cusing aSuperose 6 PC 3.2/30 column
(GE Healthcare) (flow rate 0.05 ml/min; fraction size 50 ml). Relevant SEC
fractions were analyzed by western blotting.
Cysteine Accessibility Assay
The assay followed a protocol described previously (Lambert et al., 2009), with
modifications. MBP-TAp63a, MBP-TAp63aFTL, BSA and storage buffer were574 Cell 144, 566–576, February 18, 2011 ª2011 Elsevier Inc.incubated with 2.4 mMMaleimide-PEG2-Biotin (Pierce) for 1 hr at RT. The reac-
tion was stopped by adding 44 mM cysteine followed by 1 hr incubation.
Samples were immobilized for 1 hr on a 96 well Nickel coated plate (Pierce).
Wells were then washed three times with PBS, blocked for 1 hr with 5%
skim milk in PBS, probed with either Avidin-HRP conjugate (Pierce) or HPR
conjugated anti-MBP antibody (NEB) for 50 min, washed seven times with
PBS and processed as described. Intensities were averaged over three wells.
The ratio of Avidin-HRP conjugate and HRP conjugated anti-MBP antibody
signal intensities corresponds to the cysteine accessibility. The ratio of
MBP-TAp63a was set to 100%. Each experiment was performed three times
and the results were averaged.
Multiangle Light Scattering
SEC-MALS experiments were performed at room temperature using a Super-
dex 200 5/150 GL column (GE Healthcare) at a flow rate of 0.3 ml/min. Elution
of 80 ml of purified proteins of 1 mg/ml concentration was detected using an
Optilab rEX Refractive Index Detector and a Dawn Heleos II at a Laser wave-
length of 658 nm (Wyatt Technology) to determine the weight average molar
mass MW of peak locations. Data were processed using ASTRA software
package 5.3.4.11 (Wyatt Technology).
Mice and Irradiation
Animal care and handling were performed according to the guidelines set by
theWorld Health Organization (Geneva, Switzerland). Five-day-old (P5) female
CD-1 mice were purchased from Charles River Laboratories. Animals were
divided into two groups, NIRR (nonirradiated) and IRR (irradiated). IRR mice
were exposed to 0.52 Gy of whole-body g-irradiation on a rotating turntable
in a 137Cs irradiator, at a dose rate of 2.387 Gy/min. Ovaries of both groups
were harvested after 6 hr.
Analysis of Murine Ovary Extracts
Sixteen ovaries of NIRR or IRR mice were lysed by mechanical force in 50 mM
sodium phosphate, pH = 7.2, 150 mM NaCl, 0.1% Triton X-100, EDTA free
protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail (Roche)
in a total volume of 70 ml. After centrifugation at 20,0003 g for 15min at 4C the
supernatant was injected in a Superose 6 PC 3.2/30 column (GE Healthcare)
equilibrated with 50 mM sodium phosphate, 100 mM NaCl, EDTA free
protease inhibitor cocktail and phosphatase inhibitor cocktail at 4C and
eluted as described above. Collected fractions were separated using 10%
Bis-Tris NuPAGE gels (Invitrogen) in MOPS buffer at 4C and subsequently
transferred on a Hybond-P membrane (GE Healthcare) using a XCell II blot
module (Invitrogen). Blots were then blocked with 5% skim milk in TBS buffer
containing 0.1% Tween-20 and probed over night at 4C with 4A4 (Suh et al.,
2006) antibody. Detection was performed using goat anti-mouse IgG peroxide
conjugate (Sigma Aldrich). Blots were quantified using Biometra BioDocAna-
lyze 2.0 software.
Fluorescence Anisotropy
FA experiments were performed at room temperature using a Jasco spectro-
fluorometer FP-6500 (Jasco Labortechnik). MBP-TAp63a, MBP-TAp63aFTL,
and MBP-TAp63g purified from E. coli were added to 15 nM of 50-fluores-
cein-tagged dsDNA with the sequence of the p21 promoter response element
(50-GGCAGGAACATGTCCCAACATGTTGAGCCG-30) in final monomeric
concentrations between 0.1 and 15 mM in a total volume of 500 ml. Protein
and DNA were incubated for 30 min at room temperature before being
measured with excitation at 488 nm and emission at 516 nm. Each experi-
mental series was repeated three times (MBP-TAp63a and MBP-TAp63aFTL)
or twice (MBP-TAp63g) and averaged. Data were analyzed using the software
Origin (OriginLab Corporation). Dissociation constants KD were calculated by
fitting the data to the equation shown below resembling a two-binding-site
model:
Y =
AC1K2½P+AC2½P2 +K1K2AD
K1K2 +K2½P+ ½P2
;
with Y being the measured FA, AC1, AC2, and AD the FA values of a complex
with one p63 oligomer bound to DNA, of a complex with two p63 oligomers
bound to DNA and of the free DNA, respectively, [P] the monomeric concen-
tration of the protein and K1 and K2 the two binding constants. For MBP-
TAp63aFTL and MBP-TAp63g the KD values for the second binding site
were 47.1 ± 115.7 mM and 20.8 ± 18.0 mM, respectively, suggesting that
they represent unspecific binding. For MBP-TAp63a a negative KD value of
0.021 ± 0.02 mM was obtained which we cannot interpret at the moment.
Control experiments were performed with MBP-TAp63a, MBP-TAp63aFTL,
MBP-TAp63g, and MBP-TAp63aR as described. 50-Fluorescein-tagged
dsDNA (300 nM) with either a p63 binding sequence designed on the basis
of a SELEX (Ortt and Sinha, 2006) screening (50-CCTATTCTAGACATGTGAG
GACATGTCGATACTTATTCC-30) or a random sequence (50-CGAGTTGTAA
GTCGAATTGATACCATAATGCACTACACG-30) was used.
l-Phosphatase Treatment
Thirty ovaries of IRR mice were lysed in 50 mM sodium phosphate (pH 7.2)
150 mM NaCl, EDTA free protease inhibitor cocktail (Roche), and 1.25 mM
MnCl2 in a final volume of 120 ml as described above. To one half of the lysate
15 ml of l-Protein Phosphatase (NEB), to the other 15 ml of l-Protein Phospha-
tase storage buffer were added. Both samples were incubated at 30C for
45 min. Samples were centrifuged and analyzed by SEC and western blotting
as described above.
Cell Culture Experiments
Transactivation assays of p63 isoforms and mutants as well as corresponding
western blot analyses were performed as described previously (Straub et al.,
2010). Each measurement was carried out in triplicates and averaged.
Pull-Down Experiments
Pull-down experiments with p63 isoforms and mutants expressed in RRL and
immobilized GST-TID (aa 569–616) or GST-TA (aa 1–136) as well as corre-
sponding western blot analyses were performed as described previously
(Straub et al., 2010). Each experiment was performed three times and the
results were averaged.
Western Blotting
Western blot analysis was performed as described previously (Straub et al.,
2010).
NMR Titrations
Human p63 OD (358-391) and human p63 TD (358-416) was cloned and ex-
pressed as described (Coutandin et al., 2009). Peptides (p63 TA1 [9-32] and
p63 TA1FWL with the triple mutation F16A, W20A, L23A and mutation
F10W) were ordered from Genscript (Piscataway, NJ, USA). NMR titration
experiments (up to 15-fold excess of peptide) of 15N-labeled protein samples
(100 mM) in 25 mM HEPES, 50 mM Arg, 50 mMGlu (pH 7.5) were performed at
303 K on Bruker Avance spectrometers operating at proton frequencies of 900
and 800 MHz. Spectra were analyzed with UCSF SPARKY 3.114. Structural
Models of human p63 OD based on the structure of human p73 TD (PDB ID
2KBY) are illustrated using Pymol 1.0.
Glutaraldehyde Crosslinks
MBP-TAp63a, MBP-TAp63aFTL, and MBP-TAp63g purified from E. coli at
concentrations of 0.5, 2, and 10 mM and TAp63a at concentrations of 0.5, 2,
and 4 mM were crosslinked with 0.125% (w/v) glutaraldehyde (Merck).
Samples were incubated at 16C for 3, 20, and 68 min and immediately
analyzed by SDS-PAGE using 4%–12% Bis-Tris NuPAGE gels (Invitrogen) fol-
lowed by Coomassie staining.
LILBID Mass Spectrometry
Mass spectra were recorded using the previously described LILBID-MS
method (Hoffmann et al., 2009; Morgner et al., 2007). MBP-TAp63a expressed
in E. coliwas dialyzed over night against 10 mM potassium phosphate (pH 7.6)
without NaCl.
Analytical Ultracentrifugation
Sedimentation of samples at monomer concentrations of 1–8 mM at 4C in
20 mM potassium phosphate pH 7.5, 200 mM NaCl, 2 mM dithiothreitol wasmonitored using absorbance (at 280 nm) and interference optics in a Beckman
XL-I Analytical Ultracentrifuge equipped with a Ti-50 rotor. Sedimentation
velocity experiments were performed at a rotor speed of 45,000 rpm, while
equilibrium experiments were carried out employing rotor speeds of 7000
and 9000 rpm once equilibrium conditions had been established. Analysis
of velocity data was performed using SEDFIT (Lebowitz et al., 2002), while
HETEROANALYSIS (Cole, 2004) and ULTRASPIN (www.ultraspin.mrc-cpe.
cam.ac.uk) were employed for global fitting of equilibrium scans (per protein:
three concentrations and two speeds) to simple, nonassociation models in
order to determine the average weight of the sedimenting species.
In Vitro Phosphorylation
Radiolabeling of MBP-TAp63a was performed as described previously
(Schleiff et al., 2003). The phosphorylation profile was visualized byCoomassie
staining and autoradiography.
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